<DOC>
	<DOCNO>NCT00252759</DOCNO>
	<brief_summary>The purpose study : - To estimate relative risk ILD advanced/recurrence NSCLC patient treat gefitinib compare chemotherapy treatment , ass risk factor ILD advanced/recurrence NSCLC patient undergo treatment - To provide estimate incidence ILD group advanced/recurrence NSCLC patient undergo treatment</brief_summary>
	<brief_title>Iressa Case Control Study Japan</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Advanced/recurrence NSCLC patient one chemotherapy regimen . Patients treat gefitinib chemotherapy Cohort : All advanced/recurrence NSCLC patient participate postmarketing clinical study Patients judge investigator ( ) ILD ( provisional case ) among registered cohort OR Randomly select patient without ILD ( control ) provisional case Casecontrol study : Patients enrol casecontrol study ; consent patient ILD case approximately 4 time many consent patient without ILD control randomly select cohort</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>